SCHEMBL1492403

SCHEMBL1492403

CCOC(=O)c1[nH]ccc1NC(=O)Cc1ccc(OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.54
LMNA P02545 1/20 0.54
MAPK8 P45983 7/20 0.52
MAPK10 P53779 7/20 0.52
MAPK9 P45984 6/20 0.52
HTT P42858 2/20 0.52
ALDH1A1 P00352 3/20 0.50
TP53 P04637 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
NOD2 Q9HC29 1/20 0.47
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1492349 0.87 KMT2A (0.53) SMN1; SMN2LMNAMAPK8MAPK10MAPK9
SCHEMBL31735479 0.82 POLB (0.57) LMNAMAPK8MAPK10MAPK9HTT
SCHEMBL25241521 0.81 KDM4E (0.51) LMNAMAPK10HTTALDH1A1MEN1
SCHEMBL10293980 0.77 HTT (0.52) SMN1; SMN2LMNAMAPK8MAPK10MAPK9
SCHEMBL1492325 0.76 KDM4E (0.50) SMN1; SMN2LMNAHTTALDH1A1MEN1
SCHEMBL4200796 0.75 ALDH1A1 (0.45) SMN1; SMN2LMNAHTTALDH1A1MEN1
SCHEMBL1536623 0.72 SMN1; SMN2 (0.53) SMN1; SMN2HTTALDH1A1TP53MEN1
SCHEMBL2626729 0.72 KMT2A (0.44) SMN1; SMN2LMNAHTTALDH1A1MEN1
SCHEMBL1492249 0.72 SMN1; SMN2 (0.47) SMN1; SMN2LMNAMAPK8MAPK10MAPK9
SCHEMBL1536712 0.71 MAPT (0.53) LMNAHTTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2475660-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GlaxoSmithKline LLC (US) 2012-07-18 EP disclosed
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2012-07-05 US disclosed
WO-2011029855-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2011-03-17 WO disclosed
WO-2011029855-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK GLAXOSMITHKLINE LLC (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172333-A1 PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK PRKAB1, PRKAG1, PRKAB2 SMN1; SMN2 4359/4885LMNA 4305/4885MAPK8 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.